Can Fite Biopharma Ltd
CANF0.396USD
-0.013-3.23%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.57BMarket Cap
LossP/E TTM
More Details of Can Fite Biopharma Ltd Company
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Can Fite Biopharma Ltd Info
Ticker SymbolCANF
Company nameCan Fite Biopharma Ltd
IPO dateSep 22, 2005
CEODr. Pnina Fishman, Ph.D.
Number of employees5
Security typeOrdinary Share
Fiscal year-endSep 22
Address10 Bareket Street, Kiryat Matalon
CityPETAH TIKVA
Stock exchangeTel Aviv Stock Exchange
CountryIsrael
Postal code49170
Phone97239241114
Websitehttps://www.canfite.com/
Ticker SymbolCANF
IPO dateSep 22, 2005
CEODr. Pnina Fishman, Ph.D.
Company Executives of Can Fite Biopharma Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Sari Fishman, Ph.D.
Dr. Sari Fishman, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Yoseph Borenstein
Mr. Yoseph Borenstein
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: 6 hours ago
Updated: 6 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
4.57%
Rhumbline Advisers Ltd. Partnership
0.34%
Abalone Asset Management Ltd.
0.14%
BNP Paribas Securities Corp. North America
0.10%
Two Sigma Investments, LP
0.09%
Other
94.76%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
4.57%
Rhumbline Advisers Ltd. Partnership
0.34%
Abalone Asset Management Ltd.
0.14%
BNP Paribas Securities Corp. North America
0.10%
Two Sigma Investments, LP
0.09%
Other
94.76%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
4.57%
Investment Advisor
0.69%
Research Firm
0.18%
Hedge Fund
0.09%
Other
94.47%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
32
944.19K
5.53%
+40.52K
2025Q2
29
155.14K
1.06%
-711.63K
2025Q1
30
155.14K
1.17%
-710.63K
2024Q4
28
154.43K
1.51%
-671.86K
2024Q3
26
794.33K
11.46%
+115.72K
2024Q2
26
667.93K
11.77%
+152.94K
2024Q1
24
517.69K
9.97%
+253.94K
2023Q4
29
283.94K
5.78%
+189.77K
2023Q3
28
67.77K
1.66%
-429.92K
2023Q2
28
54.74K
1.34%
-433.22K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
779.74K
4.57%
+779.74K
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
57.58K
0.34%
+19.31K
+50.47%
Jun 30, 2025
Abalone Asset Management Ltd.
23.81K
0.14%
-16.19K
-40.48%
Jun 30, 2024
BNP Paribas Securities Corp. North America
17.59K
0.1%
-5.00K
-22.14%
Jun 30, 2025
Two Sigma Investments, LP
16.06K
0.09%
+16.06K
--
Jun 30, 2025
CAPTRUST Financial Advisors
11.38K
0.07%
+741.00
+6.97%
Jun 30, 2025
Morgan Stanley & Co. LLC
9.91K
0.06%
-13.30K
-57.30%
Jun 30, 2025
UBS Financial Services, Inc.
5.51K
0.03%
+5.51K
--
Jun 30, 2025
MainStreet Advisors
3.00K
0.02%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Date
Type
Ratio
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
